Reece E A, Homko C J
Temple University, School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Philadelphia, Pennsylvania, USA.
Drug Saf. 1998 Mar;18(3):209-20. doi: 10.2165/00002018-199818030-00005.
Diabetes mellitus complicates somewhere between 1 and 20% of all pregnancies worldwide. Women with all types of diabetes, including type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus, and gestational diabetes mellitus, as well as their infants, are at increased risk for a number of different complications. However, achieving and maintaining euglycemia throughout gestation has been demonstrated to reduce the risk of adverse outcome for both the mother and her offspring. Traditional management approaches use a combination of diet, exercise, intensive insulin regimens and multiple self monitored blood glucose determinations. There are a number of newer agents available to treat diabetes mellitus; however, their safety in pregnancy has not been thoroughly tested. Although the oral hypoglycaemic drugs are not customarily used during gestation in most of the US and Europe they have had considerable use in South Africa. Animal and human studies of the teratogenic effects of these drugs have yielded conflicting data and it is difficult to distinguish between the teratogenic effects of poor maternal metabolic control and the agents themselves. This article also addresses the current state of the knowledge regarding the drug safety of a variety of medications for conditions, including hypertension and preterm labour, commonly encountered in the management of the pregnant women with diabetes mellitus.
全球范围内,糖尿病在1%至20%的妊娠中并发。患有各类糖尿病的女性,包括1型(胰岛素依赖型)和2型(非胰岛素依赖型)糖尿病以及妊娠期糖尿病的女性及其婴儿,发生多种不同并发症的风险会增加。然而,已证实整个孕期实现并维持血糖正常可降低母亲及其后代出现不良结局的风险。传统的管理方法是结合饮食、运动、强化胰岛素治疗方案以及多次自我监测血糖。有多种新型药物可用于治疗糖尿病;然而,它们在孕期的安全性尚未得到充分测试。尽管在美国和欧洲大部分地区,孕期通常不使用口服降糖药,但它们在南非有大量使用。对这些药物致畸作用的动物和人体研究得出了相互矛盾的数据,而且很难区分母体代谢控制不佳的致畸作用和药物本身的致畸作用。本文还阐述了有关糖尿病孕妇管理中常见病症(包括高血压和早产)的各种药物安全性的当前知识状况。